Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis

Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis

Abstract Introduction This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA). Methods This retrospective,...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter Youssef, Sabina Ciciriello, Talib Tahir, Joanna Leadbetter, Belinda Butcher, Miriam Calao, Nicole Walsh, Catherine O’Sullivan, Tegan Smith, Geoffrey Littlejohn
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Rheumatology and Therapy
Subjects:
Australia
Biologic disease-modifying antirheumatic drug (bDMARD)
Janus kinase inhibitor (JAKi)
Persistence
Real-world effectiveness
Remission
Online Access:https://doi.org/10.1007/s40744-024-00736-4
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items